Black Diamond Therapeutics BDTX Stock
Black Diamond Therapeutics Price Chart
Black Diamond Therapeutics BDTX Financial and Trading Overview
Black Diamond Therapeutics stock price | 1.36 USD |
Previous Close | 2.05 USD |
Open | 2.02 USD |
Bid | 0 USD x 900 |
Ask | 0 USD x 1000 |
Day's Range | 2.02 - 2.15 USD |
52 Week Range | 1.18 - 4.08 USD |
Volume | 60.57K USD |
Avg. Volume | 62.4K USD |
Market Cap | 76.68M USD |
Beta (5Y Monthly) | 1.854228 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.27 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.5 USD |
BDTX Valuation Measures
Enterprise Value | -1062227 USD |
Trailing P/E | N/A |
Forward P/E | -1.1999999 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 0.7809595 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | 0.012 |
Trading Information
Black Diamond Therapeutics Stock Price History
Beta (5Y Monthly) | 1.854228 |
52-Week Change | 4.47% |
S&P500 52-Week Change | 20.43% |
52 Week High | 4.08 USD |
52 Week Low | 1.18 USD |
50-Day Moving Average | 1.79 USD |
200-Day Moving Average | 2.03 USD |
BDTX Share Statistics
Avg. Volume (3 month) | 62.4K USD |
Avg. Daily Volume (10-Days) | 88.69K USD |
Shares Outstanding | 36.51M |
Float | 20.57M |
Short Ratio | 34.15 |
% Held by Insiders | 4.02% |
% Held by Institutions | 75.50% |
Shares Short | 1.94M |
Short % of Float | 11.21% |
Short % of Shares Outstanding | 5.32% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -31.23% |
Return on Equity (ttm) | -63.92% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -88205000 USD |
Net Income Avi to Common (ttm) | -86537000 USD |
Diluted EPS (ttm) | -2.39 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 103.37M USD |
Total Cash Per Share (mrq) | 2.83 USD |
Total Debt (mrq) | 27.45M USD |
Total Debt/Equity (mrq) | 27.96 USD |
Current Ratio (mrq) | 8.405 |
Book Value Per Share (mrq) | 2.689 |
Cash Flow Statement
Operating Cash Flow (ttm) | -76513000 USD |
Levered Free Cash Flow (ttm) | -48413752 USD |
Profile of Black Diamond Therapeutics
Country | United States |
State | MA |
City | Cambridge |
Address | One Main Street |
ZIP | 02142 |
Phone | 617 252 0848 |
Website | https://www.blackdiamondtherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 65 |
Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Q&A For Black Diamond Therapeutics Stock
What is a current BDTX stock price?
Black Diamond Therapeutics BDTX stock price today per share is 1.36 USD.
How to purchase Black Diamond Therapeutics stock?
You can buy BDTX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Black Diamond Therapeutics?
The stock symbol or ticker of Black Diamond Therapeutics is BDTX.
Which industry does the Black Diamond Therapeutics company belong to?
The Black Diamond Therapeutics industry is Biotechnology.
How many shares does Black Diamond Therapeutics have in circulation?
The max supply of Black Diamond Therapeutics shares is 56.66M.
What is Black Diamond Therapeutics Price to Earnings Ratio (PE Ratio)?
Black Diamond Therapeutics PE Ratio is now.
What was Black Diamond Therapeutics earnings per share over the trailing 12 months (TTM)?
Black Diamond Therapeutics EPS is -1.27 USD over the trailing 12 months.
Which sector does the Black Diamond Therapeutics company belong to?
The Black Diamond Therapeutics sector is Healthcare.
Black Diamond Therapeutics BDTX included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
NASDAQ Global Select Market Com NQGS | 7634.31 USD — |
+0.11
|
— — | 7233.89 USD — | 7972.89 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3856.67 USD — |
-1.22
|
— — | 3700.88 USD — | 3966.57 USD — | — - | — — |
NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}